Association of the highly prevalent TP53 R337H mutation with pediatric choroid plexus carcinoma and osteosarcoma in Southeast Brazil

Cancer

Volumn 117, Issue 10, 2011, Pages 2228-2235

  Seidinger, Ana Luiza ^a   Mastellaro, Maria José ^a   Paschoal Fortes, Fernanda ^a   Godoy Assumpção, Juliana ^a   Aparecida Cardinalli, Izilda ^a   Aparecida Ganazza, Mônica ^a   Correa Ribeiro, Raul ^b   Brandalise, Silvia Regina ^a,c   Dos Santos Aguiar, Simone ^a   Yunes, José Andrés ^a,d  

^a Boldrini Children's Cancer Center   (Brazil)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF CAMPINAS   (Brazil)

^d CENTRO INFANTIL BOLDRINI   (Brazil)

Author keywords

adrenocortical tumors; choroid plexus carcinoma; osteosarcoma; R337H; TP53

Indexed keywords

ARGININE; GENOMIC DNA; HISTIDINE; PROTEIN P53;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADRENAL CORTEX TUMOR; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; BRAZIL; CANCER RECURRENCE; CHILD; CHOROID PLEXUS PAPILLOMA; CHOROID PLEXUS TUMOR; CODON; CONTROLLED STUDY; EWING SARCOMA; GENE; GENE CLUSTER; GENE MUTATION; GENETIC ASSOCIATION; GEOGRAPHIC DISTRIBUTION; HETEROZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOMA; MAJOR CLINICAL STUDY; OSTEOSARCOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PREVALENCE; PRIORITY JOURNAL; RHABDOMYOSARCOMA; TP53 GENE;

ADRENAL GLAND NEOPLASMS; BRAZIL; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; CHOROID PLEXUS NEOPLASMS; FEMALE; GENES, P53; HUMANS; INFANT; INFANT, NEWBORN; MALE; MUTATION; OSTEOSARCOMA; PREVALENCE;

EID: 79955507146     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25826     Document Type: Article

References (27)

1. Piovesan GC,. Prevalence of the R337H TP53 Allele in the State of Parana. [dissertation; in Portuguese] Parana, Brazil: Federal University of Parana; 2006.
2. Lalloo F, Varley J, Ellis D, et al. Prediction of pathogenic mutations in patients with early onset breast cancer by family history. Lancet. 2003; 361: 1101-1102. (Pubitemid 36369565)
3. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990; 250: 1233-1238. (Pubitemid 120031831)
4. Birch JM, Hartley AL, Tricker KJ, et al. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res. 1994; 54: 1298-1304. (Pubitemid 24108072)
5. Li FP, Fraumeni JF, Mulvihill JJ, et al. A cancer family syndrome in twenty-4 kindreds. Cancer Res. 1988; 48: 5358-5362.
6. Ribeiro RC, Sandrini F, Figueiredo B, et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci U S A. 2001; 98: 9330-9335. (Pubitemid 32743916)
7. Olivier M, Hollstein M, Hainaut P,. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010; 2: 1-17.
8. Latronico AC, Pinto EM, Domenice S, et al. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J Clin Endocrinol Metab. 2001; 86: 4970-4973. (Pubitemid 33020551)
9. Figueiredo BC, Sandrini R, Zambetti GP, et al. Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation. J Med Genet. 2006; 43: 91-96. (Pubitemid 43099998)
10. Assumpcao JG, Seidinger AL, Mastellaro MJ, et al. Association of the germline TP53 R337H mutation with breast cancer in southern Brazil [serial online]. BMC Cancer. 2008; 8: 357.
11. Achatz MI, Olivier M, Calvez FL, et al. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett. 2006; 245: 96-102.
12. Brandalise SR, Pinheiro VR, Aguiar SS, et al. Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group-Protocol ALL-99. J Clin Oncol. 2010; 28: 1911-1918.
13. Sambrook J, Russel DW,. Molecular Cloning-A Laboratory Manual. Volume 2. 2nd ed. New York: Cold Spring Harbour Laboratory Press; 1989.
14. Wolff JE, Sajedi M, Brant R, Coppes MJ, Egeler RM,. Choroid plexus tumors. Br J Cancer. 2002; 87: 1086-1091.
15. Surawicz TS, McCarthy BJ, Kupelian V, et al. Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States,1990-1994. Neuro-Oncology. 1999; 1: 14-25.
16. Torres LF, de Noronha L., Scheffel DL, Pinheiro DL, Gugelmin ES Choroid plexus tumors: epidemiologic comparative study of 24 cases [in Portuguese]. Arq Neuropsiquiatr. 2004; 62: 127-130. (Pubitemid 38489828)
17. Russel-Swetek A, West AN, Mintern JE, et al. Identification of a novel TP53 germline mutation E285V in a rare case of paediatric adrenocortical carcinoma and choroid plexus carcinoma. J Med Genet. 2008; 45: 603-606.
18. Wang L, Cornford ME,. Coincident choroid plexus carcinoma and adrenocortical carcinoma with elevated p53 expression: a case report of an 18-month-old boy with no family history of cancer. Arch Pathol Lab Med. 2002; 126: 70-72. (Pubitemid 34087635)
19. Knudson AG Jr,. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971; 68: 820-823.
20. DiGiammarino EL, Lee AS, Cadwell C, et al. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nat Struct Biol. 2002; 9: 12-16. (Pubitemid 34049172)
21. Tabori U, Shlien A, Baskin B, et al. TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. J Clin Oncol. 2010; 28: 1995-2001.
22. McIntyre JF, Smith-Sorensen B, Friend SH, et al. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol. 1994; 112: 925-930. (Pubitemid 24145318)
23. Oliveira CR, Mendonca BB, Camargo OP, et al. Classical osteoblastoma, atypical osteoblastoma, and osteosarcoma. a comparative study based on clinical, histological, and biological parameters. Clinics (Sao Paulo). 2007; 62: 167-174.
24. Wada M, Bartram CR, Nakamura H, et al. Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood. 1993; 82: 3163-3169. (Pubitemid 23334946)
25. Gonzalez KD, Noltner KA, Buzin CH, et al. Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol. 2009; 27: 1250-1256.
26. Marks DI, Kurz BW, Link MP,. High incidence of potential p53 inactivation in poor outcome childhood acute lymphoblastic leukemia at diagnosis. Blood. 1996; 87: 1155-1161. (Pubitemid 26043544)
27. Michalkiewicz E, Sandrini R, Figueiredo B, et al. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol. 2004; 22: 838-845. (Pubitemid 41103595)